Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Austedo Approved to Treat Chorea in Huntington's Disease

Teva news release; 2017 Apr 3

Teva Pharmaceutical Industries Ltd. has announced that the US Food and Drug Administration (FDA) has approved Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington's disease (HD), a rare and fatal neurodegenerative disorder. Teva Pharmaceutical Industries Ltd is headquartered in Israel.

Indications: Austedo is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of chorea associated with Huntington's disease.

Dosage/administration: The starting dose is 6 mg once daily; titrate up at weekly intervals by 6 mg per day to a tolerated dose that reduces chorea, up to a maximum recommended daily dosage of 48 mg (24 mg twice daily). Total daily dosages of ≥12 mg should be administered in 2 divided doses. Tablets should be administered with food and swallowed whole; they should not be chewed, crushed, or broken.

Adverse reactions: Most common adverse reactions were somnolence, diarrhea, dry mouth, and fatigue.

Citation:

Teva announces FDA approval of AUSTEDO™ (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease. [news release]. Jerusalem, Israel: Teva Pharmaceutical Industries Ltd. April 3, 2017. http://www.tevapharm.com/news/teva_announces_fda_approval_of_austedo_deutetrabenazine_tablets_for_the_treatment_of_chorea_associated_with_huntington_s_disease_04_17.aspx. Accessed April 13, 2017.

This Week's Must Reads

Midlife Risk Factors Linked to Late-Onset Epilepsy, JAMA Neurology; ePub 2018 Jul 23; Johnson, et al

Nearly 1 Million Adults ≥55 Years Have Epilepsy, Epilepsy Behav; ePub 2018 Aug 2; Sapkota, et al

Incidental Findings Common in Stroke Patients, J Stroke Cerebrovasc Dis; ePub 2018 Aug 2; Doyle, et al

Spatial Heterogeneity of White Matter Lesions , Neurology; ePub 2018 Aug 3; Habes, et al

Poor Sleep Linked to Slow Recovery from TBI, Sleep; ePub 2018 Jul 24; Kalmbach, Conroy, et al

Must Reads in FDA Actions

FDA Approves Xeomin for Excessive Drooling, Merz North America news release; 2018 Jul 3

FDA Approves Epidiolex for Rare Epilepsy Forms, FDA news release: 2018 Jun 25

FDA Approves Medtronic’s DBS Therapy for Epilepsy, Medtronic news release; 2018 May 1

FDA Approves Expanded Use of Exparel Nerve Block, Pacira news release; 2018 Apr 6

FDA Approves Hizentra for CIDP Treatment, CSL Behring news release; 2018 Mar 16